One of the most intriguing and vexing problems in medicine is the constellation of renal functional deragements that complicate liver disease (1) (2) (3) (4) (5) (6) . Included among these derangements are the progressive impairment of renal sodium handling that leads to the formation of ascites and peripheral edema and the renal failure of liver disease. The management of these disorders is fraught with difficulties. Often, it is necessary to alter the milieu of the patients by correcting biochemical and electrolyte abnormalities with dialytic procedures. Similarly, it may be necessary to mobilize fluid, which may precipitate life-threatening emergencies, or administer requisite fluids such as bicarbonate solution or hyperalimentation. Unfortunately, hemodialysis, which often would constitute the treatment of choice, is not feasible in many patients with severe liver disease and hemodynamic instability. Thus, patients with decompensated cirrhosis frequently become hypotensive during hemodialysis (7, 8) .
The application of an alternative dialytic approach such as peritoneal dialysis is likewise fraught with difficulties. The introduction of two liters of dialysis fluid into a peritoneal cavity that may already contain 10-15 liters of ascitic fluid minimizes the gradient, thus impairing the efficiency of dialysis. Furthermore, the drainage of larger than usual volumes of peritoneal fluid following each cycle can induce substantial derangements in body fluid distribution with resultant hypotension.
Because of these difficulties and the results of preliminary studies suggesting a beneficial effect of hemofiltration (8) and dialysis of ascitic fluid (9,10), we recently carried out a pilot study of CAVU in three patients with decompensated Laennec's cirrhosis (11) . In the first two instances, CAVU was utilized in ill patients with acute renal failure and pulmonary edema to allow administration The International Journal Of Artificial Organs / Vol. 9 no. 4, 1986/ p.p. 217-218 of large amounts of fluids for resucitation or management of a coagulopathy (fresh frozen plasma) and to stabilize renal function. The last patient developed ascites unresponsive to conventional diuretic therapy, and CAVU was instituted to induce a negative fluid balance. In this patient with intractable ascites, the procedure safely induced a negative fluid balance of 4 liters without causing hemodynamic instability, bleeding or decreasiog renal function.
The recently introduced Amicon hemofilter for CAVU (Diafilter R-20 hemofilter) has been used succesfully in dialyzing critically ill patients with hemodynamic instability (12, 13) . It utilizes a large pore polysulfone membrane that can filter both small and medium sized molecules (molecular weight less than 50,000 daltons). Because the high permeability of this membrane, only a low pressure gradient is required to filter the plasma solutes and water. The patient's own arterial to venous pressure gradient is usually sufficient to maintain the filtration. The same filtration set can be used continuously for several days, and a high rate of fluid removal (O.4-12 liters/ hour) can be achieved.
In contrast to conventional hemodialysis, CAVU can remove large amounts of fluid without causing hypotension. If blood pressure decreases, fluid removal will also decrease, acting as a protective mechanism. Furthermore, CAVU removes fluid with an electrolyte composition similar to that of the patient's plasma, hence avoiding the problem of electrolyte imbalance inherent with diuretics. CAVU can remove nitrogenous wastes at a rate similar to that of peritoneal dialysis (13) . Heparinization of the extracorporeal devices is necessary, however.
In addition to permitting administration of fluids, colloid, or bicarbonate in critically ill patients, CAVU may conceivably have a beneficial effect on hepatic encephalopathy or the hepatorenal syndrome. Denis et al (14) have used the highly permeable polyacrylonitrile membrane (An 69) to dialyze 41 patients with fulminant hepatic failure and coma, and observed progressive improvement in the encephalopathy in 62% of the patients. Animal studies have also demonstrated the beneficial effect of large pore versus regular (Cuprophan) membranes in treating experimental animals with acute liver ischemia (15) . The authors proposed that middle molecules with molecular weights ranging from 5,000 to 7,000 daltons are important, and that their removal may account for the beneficial effect seen in the group dialyzed with the large pore membrane. No improvement in renal function or hepatic encephalopathy was observed in our cases, but treatment was started very late, after several complications had occurred.
In patients with massive ascites the treatment may need to be repeated several times to achieve the desired o by Wichtig Editore, 1986 0391-3988/90021 7 -02 $00.50/0 weight loss. Nevertheless, as shown in our case, after a single treatment the patient may become responsive to diuretics again, obviating the need of repeated CAVU treatments. The mechanism for the beneficial effect of CAVU is unknown. Because the fluid returned to the patient has a higher plasma protein content, it would be expected that plasma oncotic pressure would increase, at least temporarily. In addition, release of intra-abdominal pressure or removal of a sodium-retaining factor(s) may play a role.
In summary, we believe that continuous arterio-venous ultrafiltration may be beneficial in patients with decompensated liver disease and either refractory ascites or acute renal failure. Although our preliminary experience suggests that CAVU is feasible it cannot be viewed as established therapy until its value is determined by peer-reviewed clinical trials. At present CAVU selms to be sufficiently promising to warrant additional studies. We propose that a prospective study be initiated in patients in whom conservative therapy has been ineffective. Given the magnitude of the problem (5), efforts should be exerted to delineate the precise role of CAVU in the management of these patients. 
